236 related articles for article (PubMed ID: 31715329)
1. Loss of PTPRJ/DEP-1 enhances NF2/Merlin-dependent meningioma development.
Waldt N; Scharnetzki D; Kesseler C; Kirches E; Stroscher N; Böhmer FD; Mawrin C
J Neurol Sci; 2020 Jan; 408():116553. PubMed ID: 31715329
[TBL] [Abstract][Full Text] [Related]
2. Loss of the protein-tyrosine phosphatase DEP-1/PTPRJ drives meningioma cell motility.
Petermann A; Haase D; Wetzel A; Balavenkatraman KK; Tenev T; Gührs KH; Friedrich S; Nakamura M; Mawrin C; Böhmer FD
Brain Pathol; 2011 Jul; 21(4):405-18. PubMed ID: 21091576
[TBL] [Abstract][Full Text] [Related]
3. Natural history of meningioma development in mice reveals: a synergy of Nf2 and p16(Ink4a) mutations.
Kalamarides M; Stemmer-Rachamimov AO; Takahashi M; Han ZY; Chareyre F; Niwa-Kawakita M; Black PM; Carroll RS; Giovannini M
Brain Pathol; 2008 Jan; 18(1):62-70. PubMed ID: 17924978
[TBL] [Abstract][Full Text] [Related]
4. Expression of the tumor suppressor genes NF2, 4.1B, and TSLC1 in canine meningiomas.
Dickinson PJ; Surace EI; Cambell M; Higgins RJ; Leutenegger CM; Bollen AW; LeCouteur RA; Gutmann DH
Vet Pathol; 2009 Sep; 46(5):884-92. PubMed ID: 19429976
[TBL] [Abstract][Full Text] [Related]
5. EPH receptor signaling as a novel therapeutic target in NF2-deficient meningioma.
Angus SP; Oblinger JL; Stuhlmiller TJ; DeSouza PA; Beauchamp RL; Witt L; Chen X; Jordan JT; Gilbert TSK; Stemmer-Rachamimov A; Gusella JF; Plotkin SR; Haggarty SJ; Chang LS; Johnson GL; Ramesh V;
Neuro Oncol; 2018 Aug; 20(9):1185-1196. PubMed ID: 29982664
[TBL] [Abstract][Full Text] [Related]
6. Modeling NF2 with human arachnoidal and meningioma cell culture systems: NF2 silencing reflects the benign character of tumor growth.
James MF; Lelke JM; Maccollin M; Plotkin SR; Stemmer-Rachamimov AO; Ramesh V; Gusella JF
Neurobiol Dis; 2008 Feb; 29(2):278-92. PubMed ID: 17962031
[TBL] [Abstract][Full Text] [Related]
7. Nf2 gene inactivation in arachnoidal cells is rate-limiting for meningioma development in the mouse.
Kalamarides M; Niwa-Kawakita M; Leblois H; Abramowski V; Perricaudet M; Janin A; Thomas G; Gutmann DH; Giovannini M
Genes Dev; 2002 May; 16(9):1060-5. PubMed ID: 12000789
[TBL] [Abstract][Full Text] [Related]
8. Regulation of mTOR complex 2 signaling in neurofibromatosis 2-deficient target cell types.
James MF; Stivison E; Beauchamp R; Han S; Li H; Wallace MR; Gusella JF; Stemmer-Rachamimov AO; Ramesh V
Mol Cancer Res; 2012 May; 10(5):649-59. PubMed ID: 22426462
[TBL] [Abstract][Full Text] [Related]
9. The neurofibromatosis 2 tumor suppressor gene product, merlin, regulates human meningioma cell growth by signaling through YAP.
Striedinger K; VandenBerg SR; Baia GS; McDermott MW; Gutmann DH; Lal A
Neoplasia; 2008 Nov; 10(11):1204-12. PubMed ID: 18953429
[TBL] [Abstract][Full Text] [Related]
10. Crispr/Cas-based modeling of NF2 loss in meningioma cells.
Waldt N; Kesseler C; Fala P; John P; Kirches E; Angenstein F; Mawrin C
J Neurosci Methods; 2021 May; 356():109141. PubMed ID: 33753124
[TBL] [Abstract][Full Text] [Related]
11. An Essential Role for the Tumor-Suppressor Merlin in Regulating Fatty Acid Synthesis.
Stepanova DS; Semenova G; Kuo YM; Andrews AJ; Ammoun S; Hanemann CO; Chernoff J
Cancer Res; 2017 Sep; 77(18):5026-5038. PubMed ID: 28729415
[TBL] [Abstract][Full Text] [Related]
12. The expression of the MSC-marker CD73 and of NF2/Merlin are correlated in meningiomas.
Kirches E; Steffen T; Waldt N; Hebert E; Pachow D; Wilisch-Neumann A; Keilhoff G; Schneider T; Braunsdorf WEK; Warnke JP; Mawrin C
J Neurooncol; 2018 Jun; 138(2):251-259. PubMed ID: 29468444
[TBL] [Abstract][Full Text] [Related]
13. mTOR kinase inhibition disrupts neuregulin 1-ERBB3 autocrine signaling and sensitizes NF2-deficient meningioma cellular models to IGF1R inhibition.
Beauchamp RL; Erdin S; Witt L; Jordan JT; Plotkin SR; Gusella JF; Ramesh V
J Biol Chem; 2021; 296():100157. PubMed ID: 33273014
[TBL] [Abstract][Full Text] [Related]
14. Group I Paks as therapeutic targets in NF2-deficient meningioma.
Chow HY; Dong B; Duron SG; Campbell DA; Ong CC; Hoeflich KP; Chang LS; Welling DB; Yang ZJ; Chernoff J
Oncotarget; 2015 Feb; 6(4):1981-94. PubMed ID: 25596744
[TBL] [Abstract][Full Text] [Related]
15. Familial meningioma: analysis of expression of neurofibromatosis 2 protein Merlin. Report of two cases.
Maxwell M; Shih SD; Galanopoulos T; Hedley-Whyte ET; Cosgrove GR
J Neurosurg; 1998 Mar; 88(3):562-9. PubMed ID: 9488313
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of NF2 gene deletion in pediatric meningiomas using chromogenic in situ hybridization.
Begnami MD; Rushing EJ; Santi M; Quezado M
Int J Surg Pathol; 2007 Apr; 15(2):110-5. PubMed ID: 17478763
[TBL] [Abstract][Full Text] [Related]
17. Inhibition of NF2-negative and NF2-positive primary human meningioma cell proliferation by overexpression of merlin due to vector-mediated gene transfer.
Ikeda K; Saeki Y; Gonzalez-Agosti C; Ramesh V; Chiocca EA
J Neurosurg; 1999 Jul; 91(1):85-92. PubMed ID: 10389885
[TBL] [Abstract][Full Text] [Related]
18. Neurofibromatosis Type 2 (NF2) and the Implications for Vestibular Schwannoma and Meningioma Pathogenesis.
Bachir S; Shah S; Shapiro S; Koehler A; Mahammedi A; Samy RN; Zuccarello M; Schorry E; Sengupta S
Int J Mol Sci; 2021 Jan; 22(2):. PubMed ID: 33445724
[TBL] [Abstract][Full Text] [Related]
19. Activation of Yes-Associated Protein in Low-Grade Meningiomas Is Regulated by Merlin, Cell Density, and Extracellular Matrix Stiffness.
Tanahashi K; Natsume A; Ohka F; Motomura K; Alim A; Tanaka I; Senga T; Harada I; Fukuyama R; Sumiyoshi N; Sekido Y; Wakabayashi T
J Neuropathol Exp Neurol; 2015 Jul; 74(7):704-9. PubMed ID: 26049897
[TBL] [Abstract][Full Text] [Related]
20. NF2/merlin is a novel negative regulator of mTOR complex 1, and activation of mTORC1 is associated with meningioma and schwannoma growth.
James MF; Han S; Polizzano C; Plotkin SR; Manning BD; Stemmer-Rachamimov AO; Gusella JF; Ramesh V
Mol Cell Biol; 2009 Aug; 29(15):4250-61. PubMed ID: 19451225
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]